Skip to main content
Clinical Trials/DRKS00026261
DRKS00026261
Completed
Not Applicable

evaluation of atherosclerotic vascular lesions and terminal diseases as well as cardiovascular risk factors and experimental biomarkers in patients with primary sjögren-syndrome - Ath-pSS

Medizinische Hochschule Hannover in Kooperation mit der Else-Kröner-Fresenius-Stiftung0 sites317 target enrollmentSeptember 6, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
M35.0
Sponsor
Medizinische Hochschule Hannover in Kooperation mit der Else-Kröner-Fresenius-Stiftung
Enrollment
317
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 6, 2021
End Date
April 1, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Medizinische Hochschule Hannover in Kooperation mit der Else-Kröner-Fresenius-Stiftung

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria for patient population:
  • \- Age of majority (\>18\)
  • \- ability to give informed consent is given
  • \- confirmed diagnosis of primary Sjögren's syndrome (at least 2/3 criteria from the classification criteria for pSS of the American College of Rheumatology/European League Against Rheumatism 2016\)
  • \- At least 5 years cancer free survival
  • Inclusion criteria for control subjects:
  • \- Age of majority (\>18\)
  • \- Ability to give informed consent is given
  • (matched recruitment by age and sex to patient population).

Exclusion Criteria

  • Exclusion criteria for pSS patients
  • \- Active cancer or cancer that occurred less than five years ago.
  • \- Incapable of giving informed consent
  • \- not at the age of majority (\>18 yrs.)
  • \- Pregnancy
  • \- Not fulfilling at least 2/3 classification criteria as defined by the American College of Rheumatology/European League Against Rheumatism of 2016\.
  • \- known arterial occlusive diseases (peripheral arterial occlusive disease, coronary heart disease, stroke, myocardial infarction)
  • Exclusion criteria for control subjects
  • \- not at the age of majority (\>18 yrs.)
  • \- Incapable of giving informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials